Clinical trials: Cushing's Syndrome
Hyperaldosteronism, Hypercortisolism
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Background: The adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works.
- Conditions
- Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome
- Trial name
- NCT06246357
- Testing
- [68Ga]Ga-PentixaFor
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Mood Disorder, Neurobehavioral Manifestation
Adolescence, Puberty, and Emotion Regulation
The purpose of this study is to use brain imaging technology to compare how the brains of adolescents and adults are activated during tasks that involve emotional responses.
- Conditions
- Mood Disorder, Neurobehavioral Manifestation, Healthy
- Trial name
- NCT00016731
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Mental Health (NIMH)
Adrenal Insufficiency, Cushing Syndrome
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
Cortisol is an essential for life hormone secreted in a pulsatile pattern on a diurnal rhythm. Given the complexity of cortisol secretion on a circadian rhythm with pulsations, current methods of cortisol measurement have…
- Conditions
- Adrenal Insufficiency, Cushing Syndrome, Hyperaldosteronism
- Trial name
- SensoCort (NCT06008184)
- Testing
- 24 hours sampling of 4 biological fluids (blood, ISF, sweat and saliva), 24 hours sampling of ISF or sweat (after validating the correlation with blood)
- Where
- Switzerland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Cushing's Syndrome Cardiomyopathy
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Pathophysiology of Cushing's Syndrome (CS) cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several…
- Trial name
- ERGO (NCT02611258)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- Andrea M. Isidori
Adrenal Incidentaloma, Subclinical Hypercortisolism
Evaluation of New Diagnostic Indicator of Subclinical Hypercortisolism
The purpose of this study is to evaluate the serum dehydroepiandrosterone sulfate in subclinical hypercortisolism
- Trial name
- NCT04833192
- Testing
- experimental group
- Where
- China
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome, Fatty Liver Disease
NAC- NAFLD And Cushing
Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin…
- Trial name
- NAC (NCT05881005)
- Testing
- hepatic MRI
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics